Flag of the European Union EU Clinical Trials Register Help

Clinical trials for boehringer ingelheim psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43862   clinical trials with a EudraCT protocol, of which   7285   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: boehringer ingelheim psoriasis. Displaying page 1 of 1.
    EudraCT Number: 2014-001687-36 Sponsor Protocol Number: 1311.13 Start Date*: 2014-09-04
    Sponsor Name:Boehringer Ingelheim
    Full Title: An open label extension trial assessing the safety and and efficay of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis.
    Medical condition: Patients with moderate to severe chronic plaque psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000613-79 Sponsor Protocol Number: 1297.12 Start Date*: 2016-10-25
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Compar...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005117-23 Sponsor Protocol Number: 1311.3 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003622-13 Sponsor Protocol Number: 1311.28 Start Date*: 2016-03-07
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2)
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) PT (Completed) ES (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002254-20 Sponsor Protocol Number: 1297.9 Start Date*: 2017-08-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005102-38 Sponsor Protocol Number: 1311.4 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003623-65 Sponsor Protocol Number: 1311.30 Start Date*: 2016-05-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066/ABBV-066 (risankizumab) versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatm...
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed) PT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003080-56 Sponsor Protocol Number: 1368-0025 Start Date*: 2019-05-14
    Sponsor Name:Boehringer Ingelheim France
    Full Title: An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)
    Medical condition: Generalized Pustular Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Trial now transitioned) BG (Completed) ES (Ongoing) IT (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004384-48 Sponsor Protocol Number: 1311.2 Start Date*: 2013-12-13
    Sponsor Name:Boehringer Ingelheim
    Full Title: A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004573-40 Sponsor Protocol Number: 1368-0015 Start Date*: 2017-04-28
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050185 Palmoplantar pustulosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000189-41 Sponsor Protocol Number: 1368-0024 Start Date*: 2020-07-08
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Ongoing) PL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003625-34 Sponsor Protocol Number: 1311.5 Start Date*: 2016-04-13
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 / ABBV-066 / risankiumab in patients with active psoriatic arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) NL (Completed) DE (Completed) BE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003081-14 Sponsor Protocol Number: 1368-0027 Start Date*: 2020-04-16
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo ...
    Medical condition: Generalized Pustular Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) GR (Completed) FR (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Ongoing) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003078-28 Sponsor Protocol Number: 1368-0016 Start Date*: 2019-07-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-003182-17 Sponsor Protocol Number: 1407-0004 Start Date*: 2020-09-30
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis
    Medical condition: psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Completed) BG (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004328-18 Sponsor Protocol Number: 1206.5A Start Date*: 2008-01-14
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg a...
    Medical condition: Moderate to severe plaque-type psoriasis (defined as involving ≥ 10% body surface area, with minimum disease severity PASI ≥ 10 and with static PGA of at least moderate (score of at least 3)]
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004231-37 Sponsor Protocol Number: 1368-0013 Start Date*: 2019-01-22
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presentin...
    Medical condition: Generalized Pustular Psoriasis (GPP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003487-31 Sponsor Protocol Number: 1407-0005 Start Date*: 2019-07-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Phase II long-term extension study to assess the safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005368-10 Sponsor Protocol Number: 1206.5 Start Date*: 2006-07-04
    Sponsor Name:Boehringer Ingelheim GmbH & Co. KG
    Full Title: A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg a...
    Medical condition: Moderate to severe plaque-type psoriasis (defined as involving ≥ 10% body surface area, with minimum disease severity PASI ≥ 10 and with static PGA of at least moderate (score of at least 3)]
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 14:58:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA